On July 20, Shenzhen Cell Valley Chairman Shi Yuanyuan, Chief Scientist Wang Jianxun, Deputy General Manager Tang Xiaomeng, Production and R&D Director Feng Yaru, and Assistant to the Chairman Wei Zheng visited the Shanghai Fosun Kite Cell Therapy Innovation Center for exchange. Shen Hao, Chief Scientific Officer (CSO) of Fosun Kite; Wang Xiao, Senior Director of Pipeline Planning and Expansion; Zhang Weiwei, Head of the Early Research Project Team; Zhou Chunyan, Head of Exploratory Clinical Research; Xie Chenghao, Head of the Product Development Team; Xu Lei, Head of Process Development; Wang Huiyu, Head of Process Innovation; Liu Nian, Deputy Director of Pipeline Planning and Project Management; Ju Suyang, Deputy Director of Investment at Fosun Strategic Investment Center; and Guo Yixiao, R&D Assistant, extended a warm welcome and held symposium discussions.

Led by Zhang Weiwei, Head of the Early Research Project Team at Fosun Kite, the Shenzhen Cell Valley team toured the QC laboratory, R&D laboratory, and CAR-T drug GMP production workshop.

During the symposium, the Shenzhen Cell Valley and Fosun Kite teams provided detailed introductions to their respective corporate development, R&D and production pipelines, and core technological advantages. Chairman Dr. Shi Yuanyuan stated that the Shenzhen Cell Valley team and the Fosun Kite team have long maintained close communication and liaison. Both parties fully recognize their commonalities in industrial cooperation and have also seen each other's team strengths and potential. As the only CRO/CDMO service platform in China currently with GMP industrial-scale production capability for clinical-grade retroviral vectors, Shenzhen Cell Valley hopes to further deepen cooperation with the Fosun Kite team, promote complementary advantages, and achieve win-win development. CSO Dr. Shen Hao provided an in-depth analysis of the current international trends in retroviral vector usage and the domestic situation of retroviral vector use. He expressed the hope to engage in deep cooperation with Shenzhen Cell Valley, leveraging the advantages of retroviral vectors in cost, production capacity, and high transfection efficiency for certain cell therapy products. He expressed the desire to join forces with Shenzhen Cell Valley, form positive communication with industry regulatory authorities, and jointly promote the rationalization, scientificization, standardization, and normalization of the domestic CAR-T industry, as well as the innovative R&D and promotion of retroviral vector-based cell therapy products.

Finally, the two parties engaged in in-depth discussions on cooperation models in new pipeline R&D, IIT, IND filing, joint talent cultivation, and reducing CAR-T production costs. Both parties expressed their commitment to leveraging their respective strengths, cooperating sincerely, and jointly promoting the high-quality and rapid development of the entire cell therapy industry chain.

About Fosun Kite Biotechnology Co., Ltd.

Fosun Kite Biotechnology Co., Ltd. is a joint venture between Fosun Pharma and Kite (a Gilead Sciences company) in the United States, focusing on the R&D, industrialization, and commercialization of tumor cell therapy products to benefit Chinese patients.

Since its establishment in Shanghai Zhangjiang High-tech Park in early 2017, Fosun Kite has introduced the CAR-T cell drug Yescarta (Axicabtagene Ciloleucel) for the treatment of relapsed/refractory non-Hodgkin lymphoma from Kite in the United States, conducted technology transfer, and obtained authorization for local production in China. Its new drug marketing application was included in the priority review by the Center for Drug uation of the National Medical Products Administration in March 2020. On June 22, 2021, axicabtagene ciloleucel injection (trade name: Yikaida®) was officially approved by the National Medical Products Administration, becoming China's first approved cell therapy product, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Its second indication (for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma after two or more lines of systemic therapy) has been approved for clinical trials and included in the breakthrough therapy drug program.

The company's nearly 10,000-square-meter CAR-T industrialization production base was completed and officially put into use in the Zhangjiang Innovative Drug Industry Base in December 2019. In addition, the company has a 2,000-square-meter cell therapy R&D center and an innovative talent team. Through independent innovation and international cooperation, it focuses on projects in the early R&D and clinical evidence-generating stages of CAR-T, building a sustainable innovative R&D pipeline.